{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-26-000135","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.934896+00:00","generated_at":"2026-05-15T01:28:41.619887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Labcorp Q1 revenue $3.54B (+5.8%), adjusted EPS $4.25 (+10.6%); raises FY guidance","bullets":["Q1 diluted EPS $3.35 (+32.8% YoY); adjusted EPS $4.25 vs $3.84 consensus.","FY2026 guidance raised: revenue growth 5.0%–6.1%, Adj. EPS $17.70–$18.35 (midpoint $18.03, +$0.13).","Diagnostics revenue $2.76B (+5.0%); adjusted margin 16.6% (+30bps). Biopharma Labs revenue $780.6M (+8.2%).","Operating cash flow $191.5M (vs $18.5M); free cash flow $70.5M (vs -$107.5M).","Completed acquisition of Crouse Health lab assets; partnerships with CHOP, Illumina, Optum.ai, PathAI."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-26-000135","json":"https://secwatch.observer/filing/0000920148-26-000135.json","markdown":"https://secwatch.observer/filing/0000920148-26-000135.md","text":"https://secwatch.observer/filing/0000920148-26-000135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/0000920148-26-000135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/lh-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:28:41.619887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"368b4e0791156805f242bc11107f97a16d044953","claim":"LABCORP HOLDINGS INC. reported first quarter ended March 31, 2026 results: revenue $3.54 billion, net income Net Earnings Attributable to Labcorp Holdings Inc. $ 277.8 $ 212.8, EPS $3.35. Guidance raised.","evidence_excerpt":"Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance • Results from Operations for first quarter 2026 versus first quarter 2025: ◦ Revenue: $3.54 billion vs. $3.35 billion, up 5.8% ◦ Diluted EPS: $3.35 vs. $2.52, up 32.8% ◦ Adjusted EPS: $4.25 vs. $3.84, up 10.6% • Raised Full-Year Enterprise Revenue and Adjusted EPS guidance: ◦ Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint ◦ Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/0000920148-26-000135-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$3.54 billion"},{"label":"Net income","value":"Net Earnings Attributable to Labcorp Holdings Inc. $ 277.8 $ 212.8"},{"label":"EPS","value":"$3.35"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}